Market Outlook

By 2035, the U.S. Personalized Cancer Care Devices Market is projected to reach approximately USD 50.55 billion, expanding at a CAGR of 11.35% during the forecast period from 2026 to 2035. The market is estimated at USD 17.25 billion in 2025, with historical analysis covering 2021 to 2024. Values presented in this report are expressed in USD billions.

The market expanded from approximately USD 11.85 billion in 2021 to USD 15.65 billion in 2024, supported by increasing utilization of comprehensive genomic profiling, companion diagnostics, biomarker-guided therapy selection, liquid biopsy, digital pathology, artificial intelligence-assisted oncology workflows and increasingly individualized radiation and surgical planning. By 2025, personalized oncology had progressed from a specialized capability concentrated within academic cancer centers into a more broadly integrated component of U.S. oncology decision-making.

For this report, personalized cancer care devices include medical devices, in-vitro diagnostic systems, genomic and molecular testing platforms, companion diagnostic technologies, liquid-biopsy and circulating tumor DNA systems, molecular residual disease technologies, digital pathology platforms, AI-enabled diagnostic devices and patient-specific systems that materially influence cancer treatment selection, targeting, response monitoring or recurrence management. Pharmaceuticals are excluded, as are conventional oncology devices that do not contain a meaningful patient-specific diagnostic, biomarker, imaging, computational or treatment-planning function.

The addressable market is being strengthened by the sheer size and increasing complexity of U.S. cancer care. Approximately 2.04 million new cancer cases were expected in the United States in 2025, while the number of Americans living after a cancer diagnosis reached approximately 18.6 million. This growing survivor population is particularly important because personalized cancer care increasingly extends beyond initial treatment selection into molecular residual disease surveillance, recurrence monitoring, risk stratification and adaptive management.

Personalized oncology is simultaneously changing hospital procurement behavior. Cancer centers are increasingly evaluating platforms according to diagnostic yield, turnaround time, tissue requirements, number of clinically actionable biomarkers, therapy matching capability, interoperability, reimbursement potential and ability to reduce unnecessary treatment. Consequently, purchasing decisions are shifting away from isolated laboratory instruments toward integrated ecosystems linking sample preparation, sequencing, pathology, clinical interpretation and longitudinal monitoring.

The fastest value creation through 2035 is expected in liquid biopsy and molecular residual disease testing, comprehensive genomic profiling, AI-enabled digital pathology, decentralized biomarker testing and precision treatment-planning platforms. Established companion diagnostics will continue to generate substantial recurring demand, while the next growth cycle will come from devices that can repeatedly characterize tumor biology throughout a patient’s treatment journey instead of relying on a single pretreatment specimen.

 

Introduction

According to the U.S. Personalized Cancer Care Devices Market Report, personalized cancer care represents the convergence of diagnostic technology, molecular biology, medical imaging, clinical data and therapeutic decision support. The fundamental purpose of these technologies is to move cancer management away from treatment based primarily on tumor location and histology toward treatment determined by the molecular, genomic, immunologic and clinical characteristics of an individual patient’s malignancy.

The commercial importance of this shift is substantial. U.S. oncology is increasingly characterized by biomarker-specific indications, targeted therapies, immunotherapies, tumor-agnostic treatment pathways and molecularly defined patient subgroups. As the number of available therapeutic options increases, physicians require more sophisticated technologies to identify which patients are most likely to benefit, which individuals are developing resistance and which patients remain at elevated risk of recurrence after apparently successful treatment.

The clinical requirement for personalization is reinforced by improving cancer survival. Five-year relative survival across all cancers combined has reached approximately 70% for recently diagnosed U.S. patients, creating a larger population requiring repeated surveillance, survivorship management and recurrence-risk assessment. Personalized cancer care therefore addresses more than therapeutic selection. It increasingly supports longitudinal oncology management extending from initial diagnosis through treatment optimization, minimal residual disease detection, recurrence surveillance and survivorship.

The U.S. healthcare infrastructure provides a highly attractive commercialization environment for these devices. The country has more than 6,000 hospitals, over 900,000 staffed hospital beds and a dense network of National Cancer Institute-designated centers, academic hospitals, integrated delivery networks, community oncology practices, molecular diagnostic laboratories and radiation oncology facilities. At the same time, major health systems are consolidating oncology services and standardizing diagnostic pathways across large networks, making enterprise-level adoption increasingly important.

Clinical economics are becoming equally influential. Personalized testing can add diagnostic cost upfront, but health systems increasingly evaluate whether that expenditure improves overall episode economics. Avoiding ineffective therapy, reducing toxicity, selecting a targeted treatment earlier, identifying recurrence before radiographic progression or reducing repeated tissue biopsies can materially affect downstream utilization. For manufacturers, demonstrating these economic effects is becoming as important as analytical sensitivity or technical sophistication.

The U.S. market is also moving toward decentralization. Comprehensive molecular profiling historically depended heavily on specialized reference laboratories and major academic institutions. Newer automated systems, distributed sequencing platforms, digital pathology, cloud-based interpretation and standardized sample workflows are enabling regional hospitals and community oncology practices to participate more directly in precision oncology. This trend broadens the addressable customer base and reduces dependence on a limited number of tertiary centers.

From 2026 to 2035, competitive advantage will increasingly depend on whether technology companies can connect diagnosis, treatment selection and longitudinal monitoring. A platform that provides a one-time molecular profile may remain clinically valuable, but a platform capable of tracking tumor evolution, identifying resistance mutations and monitoring residual disease over multiple time points can create significantly greater lifetime value per patient.

 

Key Market Drivers: What’s Fueling the U.S. Personalized Cancer Care Devices Market Boom?

A primary market driver is the rising U.S. cancer burden combined with improved survival. More than two million Americans are now diagnosed with cancer annually, while approximately 18.6 million people were living with a history of cancer in 2025. The U.S. survivor population is projected to exceed 22 million by 2035. This combination creates simultaneous demand for devices used at diagnosis, treatment selection, active treatment and post-treatment surveillance.

The second driver is the increasing importance of biomarker-defined cancer therapy. Oncology treatment decisions increasingly depend on EGFR, ALK, ROS1, BRAF, HER2, KRAS, BRCA1/2, PIK3CA, ESR1, PD-L1, homologous recombination repair, microsatellite instability, tumor mutational burden and other molecular characteristics. As therapeutic labels become more biomarker-specific, testing increasingly becomes an operational prerequisite rather than an optional diagnostic enhancement.

A third driver is rapid adoption of next-generation sequencing and comprehensive genomic profiling. Broad-panel testing can identify multiple potentially actionable alterations from a limited tumor specimen, making it especially valuable in lung cancer and other malignancies where sequential single-gene testing can consume tissue and delay treatment. Improvements in automation, sequencing efficiency, informatics and clinical interpretation are reducing implementation barriers across hospital laboratories.

A fourth market driver is the emergence of liquid biopsy. Plasma-based testing can help identify actionable tumor alterations when tissue is unavailable, difficult to obtain or insufficient for broad molecular testing. The ability to repeat blood-based testing also creates a fundamentally different commercial model from one-time tissue profiling. As clinical applications expand from advanced-disease genotyping to recurrence and molecular residual disease monitoring, test frequency per patient can increase substantially.

A fifth driver is molecular residual disease and recurrence surveillance. Personalized tumor-informed ctDNA assays are emerging as an important next stage in cancer management. The clinical objective is to identify microscopic residual disease after surgery or systemic therapy earlier than conventional imaging. This creates opportunities in colorectal, bladder, breast, lung and other solid tumors and may eventually influence decisions regarding adjuvant therapy escalation or de-escalation.

A sixth driver is the rapid digitization of anatomic pathology. Pathology remains central to almost every cancer diagnosis, yet workflows historically depended on physical glass slides and manual interpretation. Whole-slide imaging, computational pathology and AI-assisted pattern recognition are converting pathology into a scalable digital data environment. Personalized oncology increasingly requires integration of morphology with molecular and clinical information, making digital pathology strategically important.

The seventh driver is the economic pressure to select the right therapy earlier. Many advanced cancer therapies carry substantial treatment costs, and ineffective therapy can create avoidable toxicity, hospitalization and disease progression. Payers, oncology practices and health systems therefore have a strong financial incentive to improve patient selection. Personalized diagnostic devices become commercially attractive when they can demonstrate that a relatively small diagnostic expenditure improves the productivity of a much larger therapeutic expenditure.

The eighth driver is expansion of value-based oncology models. U.S. payment models increasingly emphasize coordinated, evidence-based, patient-centered cancer care and accountability for total episode costs. This creates greater demand for technologies that support treatment selection, patient stratification, monitoring and documentation of outcomes. Oncology practices operating under financial accountability have stronger incentives to avoid unnecessary intervention and identify deterioration earlier.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation is moving the personalized cancer care market from static testing toward dynamic tumor characterization. Traditionally, tumor biology was assessed primarily at diagnosis using a biopsy obtained at a single point in time. Cancer, however, evolves under therapeutic pressure. Resistant clones can emerge, biomarker expression can change and metastatic lesions can diverge from the original tumor. Technologies capable of repeatedly evaluating molecular status are therefore becoming increasingly valuable.

One major innovation area is high-content NGS oncology profiling. Modern panels can assess hundreds of cancer-associated genes while simultaneously evaluating single nucleotide variants, insertions, deletions, amplifications, fusions and genomic signatures such as microsatellite instability and tumor mutational burden. Competitive differentiation is increasingly based on usable clinical information rather than panel size alone. Faster turnaround, lower tissue input, better fusion detection and improved treatment interpretation are becoming critical purchase criteria.

Liquid biopsy is another defining innovation cycle. Advanced plasma-based systems can identify circulating tumor DNA without requiring a new invasive tumor biopsy. The strategic significance extends beyond convenience. Repeated plasma testing may help detect resistance mechanisms, characterize heterogeneous metastatic disease and monitor molecular response over time. As sensitivity improves, liquid biopsy is expanding into earlier-stage cancer and residual-disease applications.

Tumor-informed MRD platforms represent an especially important development. These technologies create a patient-specific molecular signature from the individual’s tumor and subsequently search for those alterations in blood. Their personalized architecture differentiates them from fixed-panel assays and makes MRD one of the clearest examples of individualized diagnostic device design.

Digital pathology is advancing through AI-assisted quantitative interpretation. Algorithms can assist pathologists in identifying malignant tissue, grading tumors, quantifying biomarkers and prioritizing suspicious slides. Rather than replacing pathologists, the strongest commercial applications are likely to reduce repetitive work, improve consistency and expand access to specialist-level interpretation across distributed hospital networks.

Precision is also expanding into therapeutic delivery. Radiation oncology systems increasingly use multimodality imaging, deformable image registration, adaptive planning, motion management and AI-based contouring to personalize radiation dose around each patient’s anatomy. In selected surgical oncology applications, image-guided navigation, intraoperative imaging and robotic platforms similarly enable treatment strategies tailored to individual anatomy and tumor location.

Manufacturers are also differentiating through workflow integration. A technically superior assay can still fail commercially if ordering is complex, turnaround is unpredictable or results are difficult to incorporate into the electronic health record. Leading platforms increasingly connect specimen tracking, laboratory workflow, variant interpretation, clinical reporting, treatment matching and longitudinal monitoring. This reduces administrative burden and makes precision oncology more practical in high-volume community settings.

 

Segmentation Insights

The U.S. Personalized Cancer Care Devices Market is segmented on the basis of product and device type, cancer type, clinical application, end user and region.

 

By Product and Device Type

Molecular Profiling and NGS Systems

Molecular profiling and NGS systems represent one of the largest foundational categories in personalized cancer care. These platforms include sequencing instruments, oncology panels, library-preparation technologies, reagents, analytical software and associated workflow systems. Demand is supported by the continuing expansion of biomarker-driven treatment across solid tumors and hematologic malignancies. Comprehensive profiling is increasingly preferred for complex cancers where multiple actionable alterations may exist and limited tissue makes sequential testing inefficient.

The competitive direction of this segment is shifting from maximum sequencing breadth toward clinically efficient sequencing. Cancer centers increasingly measure how frequently a platform produces actionable information, how quickly results are available and how reliably testing can be completed from small biopsies. Laboratories also evaluate throughput, reagent cost, automation requirements and bioinformatics burden.

Companion Diagnostic and Biomarker Testing Devices

Companion diagnostic devices remain one of the most commercially established personalized oncology categories. They include immunohistochemistry assays, molecular PCR tests, fluorescence in-situ hybridization systems, NGS-based companion diagnostics and other FDA-authorized tests associated with specific therapeutic products or groups of therapies.

The segment benefits from a powerful commercial mechanism: when a drug label requires biomarker testing, diagnostic utilization is directly connected to therapeutic adoption. Breast, lung, prostate, colorectal, ovarian, melanoma and hematologic cancers collectively generate significant companion-diagnostic demand. Manufacturers with broad biomarker portfolios can also strengthen relationships with pharmaceutical developers by supporting clinical trials and co-development programs.

Liquid Biopsy and ctDNA/MRD Systems

Liquid biopsy and ctDNA technologies are expected to be the fastest-growing product category through 2035. Plasma-based genomic profiling is increasingly used in advanced cancers when tissue is unavailable or when clinicians need a less invasive method to reassess molecular status. Unlike conventional tissue testing, blood-based technologies can support repeated testing and therefore generate a larger longitudinal revenue opportunity.

MRD represents the most strategically important growth frontier. Tumor-informed assays can create personalized molecular fingerprints and monitor whether microscopic disease remains after treatment. Wider clinical adoption will depend on prospective evidence showing that acting on MRD results improves outcomes, but the opportunity is considerable because surveillance can involve multiple tests over several years.

Digital Pathology and AI-Assisted Oncology Devices

Digital pathology and AI-assisted diagnostic systems form an emerging but rapidly expanding category. Whole-slide imaging converts pathology specimens into high-resolution digital data, while AI algorithms can support tumor detection, grading, biomarker interpretation and workflow prioritization.

The U.S. opportunity is particularly attractive for large health systems seeking centralized subspecialty pathology coverage. A digital slide can be interpreted remotely, facilitating enterprise pathology networks and reducing dependence on the physical movement of specimens. As pathology becomes increasingly integrated with genomic data, these systems will become an important infrastructure layer for personalized oncology.

Personalized Imaging, Navigation and Treatment-Planning Systems

This segment includes technologies that adapt cancer treatment to patient-specific anatomy, tumor location or imaging characteristics. Examples include adaptive radiation-planning systems, AI-based contouring, image-guided radiation therapy, surgical navigation, advanced treatment-planning software and selected robotic or intraoperative visualization technologies.

Revenue growth is supported by hospitals’ desire to increase targeting accuracy while protecting healthy tissue and standardizing complex planning. These systems are capital intensive, but they can support high-value oncology service lines and strengthen the competitive position of comprehensive cancer centers.

 

By Cancer Type

Lung Cancer

Lung cancer is one of the most important markets for personalized cancer care devices because treatment selection increasingly depends on molecular profiling. EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK and HER2 alterations, along with PD-L1 expression, can influence therapeutic decisions. Small tissue biopsies and advanced-stage presentation also make efficient multiplex testing and liquid biopsy especially valuable.

The segment will remain a major commercial priority because molecular retesting can be required when resistance develops. This creates opportunities for both tissue-based comprehensive genomic profiling and repeated plasma-based testing.

Breast Cancer

Breast cancer generates substantial personalized-device demand through HER2 testing, hormone receptor evaluation, genomic risk assessment, BRCA testing, PIK3CA analysis and increasingly ESR1 mutation detection. Molecular information influences treatment across early and metastatic disease.

The breast cancer segment is also well positioned for expansion of recurrence-risk and MRD technologies because the large survivor population creates long-term monitoring demand. Diagnostic platforms capable of influencing both therapy selection and surveillance can generate attractive lifetime patient value.

Colorectal Cancer

Colorectal cancer requires increasing biomarker stratification across KRAS, NRAS, BRAF, MSI/MMR and HER2-related pathways. Molecular testing is particularly important in metastatic disease, while ctDNA is increasingly being evaluated for postoperative residual-disease detection and recurrence monitoring.

This makes colorectal cancer strategically important for MRD developers. The large population of surgically treated patients creates an opportunity to use molecular surveillance to identify individuals at greatest recurrence risk and potentially personalize adjuvant treatment intensity.

Prostate Cancer

Personalized prostate cancer care is expanding beyond conventional PSA-driven management. Genomic classifiers, hereditary cancer testing, homologous recombination repair profiling, BRCA-associated therapeutic selection, advanced imaging and molecular treatment planning are creating a more differentiated technology market.

Advanced prostate cancer is increasingly relevant to companion diagnostic developers because DNA repair alterations can guide targeted treatment. At the same time, localized disease creates demand for technologies that help distinguish aggressive tumors from cancers that may be managed more conservatively.

Hematologic Malignancies

Leukemia, lymphoma and multiple myeloma have long depended on molecular classification, flow cytometry, cytogenetics and increasingly NGS. Personalized testing can identify mutations, chromosomal abnormalities and measurable residual disease that influence treatment intensity and prognosis.

MRD monitoring is especially established conceptually in hematologic malignancies because very low levels of persistent disease can provide clinically relevant information. This makes hematology an important technology-development environment for highly sensitive molecular assays.

Other Solid Tumors

Melanoma, ovarian, endometrial, bladder, pancreatic, thyroid, brain and other cancers collectively represent a growing personalized-device opportunity. Tumor-agnostic biomarkers are particularly important because some therapeutic eligibility is now determined by molecular characteristics rather than tissue of origin.

Rare cancers can also benefit disproportionately from comprehensive profiling because conventional treatment options may be limited. As sequencing cost declines, testing smaller cancer populations becomes increasingly economically feasible.

 

By Clinical Application

Patient Stratification and Therapy Selection

Therapy selection is currently the largest personalized cancer care application. Devices identify molecular, genomic or protein biomarkers that determine whether a patient qualifies for targeted therapy, immunotherapy or another biomarker-directed treatment.

The commercial importance of this application is reinforced by the increasing cost and complexity of cancer drugs. Health systems and payers have little incentive to fund an expensive therapy for a patient unlikely to benefit, making accurate stratification economically valuable.

Treatment Planning and Targeting

Personalized treatment-planning devices use patient-specific anatomy, imaging and computational information to optimize therapy delivery. Radiation oncology is the largest application, with adaptive planning and image guidance enabling clinicians to modify treatment according to tumor size, organ position and anatomical change.

Surgical navigation and image-guided intervention also contribute to this segment. Growth is strongest where precision can reduce collateral tissue injury, improve margin control or enable minimally invasive treatment.

Molecular Residual Disease and Recurrence Monitoring

MRD and recurrence monitoring are expected to produce some of the highest growth rates in the market. The objective is to detect evidence of persistent or recurrent malignancy before conventional imaging identifies macroscopic disease.

The commercial model is attractive because monitoring is longitudinal. One patient may require repeated tests at defined intervals, creating recurring revenue rather than a one-time diagnostic transaction. The segment’s ultimate scale will depend on clinical utility evidence and payer coverage.

Treatment Response and Resistance Monitoring

Cancer treatment can exert selective pressure that changes the molecular composition of a tumor. Repeated tissue biopsy is often impractical, making liquid biopsy particularly useful for detecting emerging resistance alterations.

This application is likely to expand as oncology becomes more adaptive. Instead of maintaining treatment until radiographic progression, future pathways may increasingly use molecular information to determine when therapy should be modified.

Risk Assessment, Prognostic Profiling and Survivorship Management

Personalized devices also support decisions before and after active therapy. Germline testing can identify inherited cancer susceptibility, while genomic signatures can help estimate recurrence risk or identify patients who may benefit from more intensive treatment.

As the survivor population expands, survivorship management will become a larger commercial opportunity. Technology developers that link risk stratification, surveillance and longitudinal patient data can participate in care well beyond the initial treatment episode.

 

By End User

Hospitals and Integrated Health Systems

Hospitals and health systems represent the largest end-user category because they combine oncology treatment, pathology, imaging, surgery, radiation and laboratory services. Large systems increasingly pursue enterprise molecular testing strategies to standardize pathways across multiple hospitals.

Procurement committees evaluate platforms through total clinical and operational value. Integration with electronic medical records, pathology systems and clinical decision support can materially influence purchasing alongside analytical performance.

Academic Medical Centers and Comprehensive Cancer Centers

Academic and comprehensive cancer centers remain the most important early adopters of advanced personalized oncology technology. These institutions conduct clinical trials, maintain molecular tumor boards and frequently manage rare or highly complex cancers.

They are strategically important to manufacturers because adoption within prestigious cancer centers can generate clinical evidence, physician advocacy and broader community adoption.

Molecular Diagnostic and Reference Laboratories

Reference laboratories provide significant testing capacity for hospitals and oncology practices that lack local genomic infrastructure. They remain central to comprehensive genomic profiling, liquid biopsy and specialized molecular testing.

Competition increasingly depends on turnaround time, payer coverage, clinical interpretation and logistical simplicity. Laboratories able to return complex genomic information in a clinically actionable format can maintain strong positions even as hospital systems expand in-house testing.

Community Oncology Practices

Community oncology is becoming increasingly important because most U.S. cancer patients receive at least part of their care outside major academic centers. Precision oncology cannot achieve national scale unless testing can be ordered, interpreted and acted upon efficiently in these settings.

Community practices prioritize simplified ordering, dependable reimbursement, fast turnaround and treatment-relevant reporting. Platforms requiring extensive local molecular expertise face greater barriers in this segment.

Ambulatory Cancer Centers and Specialty Treatment Facilities

Ambulatory radiation centers, specialty cancer clinics and other outpatient facilities are increasing their use of personalized treatment planning, imaging, molecular diagnostics and monitoring. As oncology care migrates away from inpatient settings, these facilities will become a larger purchaser of compact and workflow-efficient technologies.

 

Regional Insights: Where the Market is Growing Fastest

The market is geographically segmented into the South, Northeast, West and Midwest. Regional demand varies according to cancer case volume, demographics, concentration of academic cancer centers, molecular laboratory infrastructure, specialist density, reimbursement environment and willingness of health systems to adopt advanced oncology technology.

The South held the largest modeled share in 2025, while the West is expected to record the fastest CAGR through 2035.

South

The South represented an estimated USD 6.21 billion in 2025, making it the largest regional U.S. personalized cancer care devices market. The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, Tennessee, Alabama, Mississippi, Louisiana, Arkansas, Kentucky, West Virginia and Oklahoma, among other Southern markets.

Population scale is the primary advantage. Texas alone is projected to record more than 160,000 new cancer diagnoses in 2026, while Florida is expected to exceed 180,000. These volumes create substantial demand for molecular profiling, companion diagnostics, liquid biopsy and individualized treatment planning.

Texas is one of the most important state markets in the country. Houston, Dallas-Fort Worth, Austin and San Antonio support extensive oncology infrastructure, including major academic cancer programs, integrated health systems and private oncology networks. Houston is particularly influential because of its concentration of high-acuity cancer care and clinical research. The state’s scale also supports decentralized testing models capable of serving patients outside major metropolitan areas.

Florida has a different but equally attractive profile. Its large older population creates significant demand across prostate, breast, lung, colorectal and hematologic cancers. The state’s extensive oncology practice networks and high Medicare exposure make clinical utility, reimbursement and care coordination especially important. Liquid biopsy and minimally disruptive surveillance technologies are attractive because they can reduce the need for repeated invasive procedures in older patients.

North Carolina is emerging as another precision oncology hub through major academic systems and its broader life-sciences ecosystem. Georgia and Tennessee support growing cancer populations and substantial metropolitan oncology capacity in Atlanta and Nashville. Virginia and Maryland benefit from sophisticated hospital systems, research institutions and proximity to federal biomedical infrastructure.

The South also contains states with high cancer mortality and major rural populations. Kentucky, Mississippi, West Virginia and parts of Alabama, Arkansas and Louisiana face significant cancer burden but uneven access to tertiary oncology centers. This produces an important commercial requirement for technologies that can decentralize precision care. Blood-based testing, digital pathology consultation and cloud-based molecular decision support can potentially extend advanced capabilities to communities that cannot maintain a full genomic laboratory locally.

By 2035, the Southern market is projected to approach USD 18.00 billion, representing an estimated regional CAGR of approximately 11.23%.

West

The West represented approximately USD 3.97 billion in 2025 but is expected to be the fastest-growing regional market, expanding at an estimated CAGR of approximately 13.35% and approaching USD 13.90 billion by 2035.

California is the dominant state market. More than 200,000 new cancer diagnoses are projected in the state in 2026, giving California one of the largest oncology patient pools in the country. Its importance, however, extends beyond clinical volume. California combines leading academic cancer centers, biotechnology companies, sequencing developers, digital-health businesses, AI companies and venture-backed oncology technology firms.

This ecosystem creates unusually rapid diffusion of technologies such as genomic profiling, liquid biopsy, computational pathology and AI-assisted oncology. California health systems also have experience integrating digital technologies into large-scale clinical workflows, making the state an important launch market for next-generation devices.

Washington is another strategically important market because of its strong research infrastructure and technology orientation. Oregon similarly supports sophisticated integrated health systems that can evaluate technology according to population-level outcomes. Arizona and Nevada are expanding because of rapid population growth and increasing older-adult populations, creating stronger demand for cancer services.

Colorado and Utah combine research-oriented providers with growing metropolitan populations. Utah is particularly relevant to genomic medicine because of its established genetics and life-sciences capabilities. New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii are smaller device markets, but their geographic characteristics make remote pathology, tele-oncology integration and decentralized molecular testing particularly relevant.

The West will gain market share through 2035 because the technologies growing fastest nationally—AI pathology, liquid biopsy, cloud-based clinical interpretation and integrated genomic platforms—align strongly with the region’s provider and technology ecosystem.

Northeast

The Northeast accounted for an estimated USD 4.12 billion in 2025 and is projected to reach approximately USD 11.20 billion by 2035, representing a CAGR of about 10.52%.

The region includes New York, Massachusetts, Pennsylvania, New Jersey, Connecticut, Maine, Vermont, New Hampshire, Rhode Island and Delaware. Although its population growth is slower than the South or West, the Northeast has one of the highest concentrations of academic hospitals, cancer specialists, pathology expertise and clinical-trial infrastructure in the country.

New York is the largest state market in the region, with approximately 126,000 new cancer diagnoses projected in 2026. Major New York cancer centers manage large volumes of complex and advanced disease and are important adopters of comprehensive profiling, liquid biopsy and experimental biomarker technologies.

Massachusetts has a smaller patient population but outsized strategic influence. Its concentration of academic medicine, biotechnology, genomics and pharmaceutical research makes it a major environment for diagnostic development and clinical validation. Technologies adopted within Boston’s oncology ecosystem can influence clinical practice nationally.

Pennsylvania provides another large patient and health-system base, while New Jersey combines substantial oncology demand with a significant pharmaceutical and life-sciences presence. Connecticut benefits from strong academic and health-system infrastructure.

Procurement in the Northeast tends to be evidence intensive. Cancer centers often require analytical validation, prospective clinical data, peer-reviewed evidence and integration with multidisciplinary tumor boards before broad adoption. This raises entry barriers but can also support premium pricing for clinically differentiated platforms.

The region is expected to remain especially strong in complex molecular diagnostics, clinical trials, digital pathology, advanced radiation planning and high-acuity personalized oncology.

Midwest

The Midwest represented approximately USD 2.95 billion in 2025 and is expected to reach about USD 7.45 billion by 2035, reflecting an estimated CAGR of approximately 9.71%.

The region includes Illinois, Ohio, Michigan, Minnesota, Indiana, Wisconsin, Missouri, Iowa, Kansas, Nebraska, North Dakota and South Dakota. Its market profile combines major academic cancer centers with extensive community hospital networks and substantial rural populations.

Illinois is a major market due to Chicago’s large healthcare ecosystem and concentration of academic institutions. Ohio is another important cancer care center, with more than 78,000 new cancer cases projected in 2026 and substantial tertiary oncology capacity. Michigan supports large integrated health systems and strong demand for breast, lung, prostate and hematologic cancer management.

Minnesota is strategically important because of its broader medical-device and diagnostic ecosystem. Wisconsin, Indiana and Missouri provide sizeable community oncology markets where manufacturers can scale established platforms through regional health systems.

Iowa, Kansas, Nebraska and the Dakotas offer smaller absolute revenue pools but create demand for decentralized precision oncology. Rural distance can make centralized pathology and repeated invasive testing challenging. Digital pathology, blood-based biomarker testing and streamlined send-out genomic services can therefore generate disproportionate clinical value.

The Midwest is expected to expand somewhat more slowly than the national average, but it remains attractive for vendors able to demonstrate reliability, reimbursement support, economical testing and integration across large multihospital networks.

 

Key Market Players

The U.S. Personalized Cancer Care Devices competitive landscape is fragmented across molecular diagnostics, genomic sequencing, liquid biopsy, companion diagnostics, pathology, AI, imaging and personalized treatment planning. Unlike conventional medical-device markets, no single manufacturer dominates the complete personalized cancer care pathway.

Some of the major companies and strategically relevant participants include:

Roche Diagnostics
Foundation Medicine
Guardant Health
Natera
Illumina
Thermo Fisher Scientific
QIAGEN
Agilent Technologies
Abbott Laboratories
Myriad Genetics
Exact Sciences
Caris Life Sciences
Tempus AI
NeoGenomics Laboratories
Personalis
Adaptive Biotechnologies
Danaher / Leica Biosystems
Bio-Rad Laboratories
Hologic
Siemens Healthineers / Varian
GE HealthCare
Philips
Elekta
Paige
PathAI

Roche occupies a particularly strong position because its capabilities extend across tissue diagnostics, companion diagnostics and comprehensive genomic profiling through Foundation Medicine. This breadth enables the company to participate in both traditional pathology and high-value precision oncology.

Guardant Health is strategically important in liquid biopsy and plasma-based comprehensive genomic profiling, while Natera has become highly relevant to personalized tumor-informed molecular residual disease. Illumina and Thermo Fisher provide major sequencing infrastructure and oncology panels that support both centralized and distributed genomic testing.

QIAGEN, Agilent and Abbott maintain strong positions across companion diagnostics, molecular testing and biomarker analysis. Myriad is particularly important in hereditary cancer and therapy-linked genomic testing.

Caris, Tempus and NeoGenomics illustrate how competition increasingly extends beyond physical instrumentation. Clinical datasets, molecular interpretation and decision-support capabilities can create substantial differentiation because oncologists ultimately require clinically actionable answers rather than raw sequencing information.

Siemens Healthineers, Varian, Elekta, GE HealthCare and Philips participate in the personalization of therapeutic planning through oncology imaging, radiation therapy and treatment-guidance ecosystems. Paige and PathAI demonstrate the emerging competitive importance of AI-enabled pathology.

Over the forecast period, market leadership will increasingly depend on clinical evidence, FDA authorization, reimbursement coverage, integration with pharmaceutical development, access to longitudinal clinical data, turnaround time and ability to embed testing within routine oncology workflow.

 

Recent Developments

Recent U.S. market developments demonstrate that personalized cancer care is moving deeper into regulated clinical practice.

In May 2026, FDA approval of a personalized tumor-informed Signatera CDx application for circulating tumor DNA molecular residual disease in muscle-invasive bladder cancer represented a significant milestone. The approval connects a patient-specific MRD assay to treatment selection and demonstrates how ctDNA technologies are moving from generalized recurrence-risk research toward regulated companion-diagnostic applications.

During May 2026, Guardant’s liquid-biopsy platform also received important U.S. regulatory expansion, reinforcing plasma-based comprehensive genomic profiling across breast, colorectal and non-small-cell lung cancer indications. These developments support the broader transition toward blood-based molecular decision-making.

In June 2026, the U.S. regulatory profile of Illumina’s TruSight Oncology Comprehensive platform continued to expand. The system evaluates hundreds of genes and reports clinically relevant genomic characteristics including tumor mutational burden and microsatellite instability, illustrating the increasing complexity of modern personalized oncology diagnostics.

In July 2026, PGDx elio tissue complete CDx received U.S. approval for a companion diagnostic application, further demonstrating the movement toward broader NGS panels capable of simultaneously identifying multiple classes of genomic alterations.

The regulatory environment is also increasingly accommodating combinations of diagnostic and therapeutic development. Companion diagnostics now cover a wide range of biomarkers and cancer indications, and drug developers increasingly design clinical programs alongside molecular testing strategies. Diagnostic manufacturers capable of participating early in pharmaceutical development can therefore create commercially valuable long-term partnerships.

Value-based cancer care is influencing the market simultaneously. The CMS Enhancing Oncology Model has expanded to approximately 3,000 practitioners across roughly 500 sites in 33 states and Washington, D.C. The model emphasizes patient-centered, coordinated and evidence-based oncology care. Such payment models are strategically aligned with personalization because they reward practices for avoiding unnecessary utilization and improving care quality rather than maximizing individual service volume.

The next wave of developments is expected to focus on expanded MRD indications, broader liquid-biopsy use in earlier-stage disease, AI-assisted pathology, decentralized sequencing and integrated platforms connecting molecular data directly with treatment pathways.

 

Conclusion

The U.S. Personalized Cancer Care Devices Market Size & Share is positioned for rapid expansion from approximately USD 17.25 billion in 2025 to USD 50.55 billion by 2035, representing a projected CAGR of 11.35% from 2026 to 2035.

The central economic driver is not simply rising cancer incidence. The more important structural change is the increasing amount of patient-specific information required to make an oncology treatment decision. Cancer care is progressively being divided into smaller molecular subgroups, creating demand for technologies capable of identifying those subgroups accurately and quickly.

Comprehensive genomic profiling will remain a core market foundation, while liquid biopsy and molecular residual disease are expected to generate the strongest incremental growth. Companion diagnostics will benefit from continued biomarker-driven drug development, and digital pathology will become increasingly important as hospital systems digitize diagnostic workflows and integrate pathology with genomic and clinical data.

The shift toward longitudinal cancer management will materially reshape device economics. Historically, many personalized diagnostics generated revenue from a single test at the start of treatment. Emerging monitoring technologies can create repeated interactions throughout a patient’s care pathway. This change from one-time profiling to continuous molecular surveillance represents one of the most important commercial opportunities through 2035.

Hospital procurement will also become more demanding. Buyers will increasingly expect evidence that personalized technologies improve more than diagnostic accuracy. Vendors will need to demonstrate faster treatment initiation, higher actionable finding rates, reduced unnecessary therapy, fewer invasive procedures, improved laboratory productivity and better total episode economics.

Regional opportunity will remain led by the South because of its population scale and rapidly expanding cancer-care infrastructure. The West will record the fastest growth, driven by California’s oncology and technology ecosystem and early adoption of liquid biopsy, AI and digital care. The Northeast will remain the most evidence-intensive premium market, while the Midwest will provide a large, stable opportunity for technologies that can decentralize precision oncology across integrated and rural networks.

Texas, Florida, California and New York will remain the most commercially consequential individual state markets because their patient populations can support significant testing volume. Massachusetts will remain disproportionately influential in innovation and clinical validation, while North Carolina, Georgia, Arizona, Colorado, Ohio, Illinois, Michigan and Pennsylvania offer attractive secondary expansion opportunities.

For companies evaluating this market, the strategic question is no longer whether personalized oncology will become embedded in U.S. cancer care. That transition is already underway. The critical questions are which diagnostic technologies will move into routine reimbursement, how frequently patients will be tested during the cancer journey, which platforms can prove clinical utility rather than analytical capability alone, and which vendors can integrate molecular information into real-world oncology workflow at scale.

Companies that combine regulatory credibility, clinically actionable data, rapid turnaround, reimbursement support, workflow integration and longitudinal patient monitoring will be positioned to capture a disproportionate share of the approximately USD 33.30 billion in incremental market value expected to emerge between 2025 and 2035.

 

TABLE OF CONTENT

1. U.S. Personalized Cancer Care Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Molecular Diagnostic and Genomic Testing Companies
1.6.2. Companion Diagnostic Developers
1.6.3. Liquid Biopsy and MRD Technology Providers
1.6.4. Digital Pathology and AI Oncology Companies
1.6.5. Imaging, Navigation and Precision Treatment System Manufacturers
1.6.6. Hospitals, Integrated Health Systems and Comprehensive Cancer Centers
1.6.7. Molecular Diagnostic and Reference Laboratories
1.6.8. Community Oncology Practices and Ambulatory Cancer Centers
1.6.9. Pharmaceutical and Biopharmaceutical Companion Diagnostic Partners
1.6.10. Commercial Payers, Medicare, Regulators and Clinical Decision-Makers

What this section provides: This section defines the personalized cancer care device market boundary, study scope, methodology, assumptions and stakeholder ecosystem so clients understand how the U.S. market is measured, classified and validated.

2. U.S. Personalized Cancer Care Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size Opportunity, 2025–2035
2.8. High-Growth Opportunity Areas
2.8.1. Comprehensive Genomic Profiling
2.8.2. Liquid Biopsy and ctDNA Testing
2.8.3. Molecular Residual Disease Monitoring
2.8.4. Companion Diagnostics
2.8.5. Digital Pathology and AI-Assisted Oncology
2.8.6. Personalized Treatment Planning and Navigation
2.9. Major Commercial and Investment Themes

What this section provides: This section gives decision-makers a concise view of market size, growth trajectory, leading technology categories, clinical adoption trends, competitive intensity and priority opportunity areas through 2035.

3. U.S. Personalized Cancer Care Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Cancer Incidence and Expanding Cancer Survivor Population
3.1.2. Growing Adoption of Biomarker-Directed Oncology Therapies
3.1.3. Expansion of Comprehensive Genomic Profiling and NGS Testing
3.1.4. Increasing Utilization of Liquid Biopsy and ctDNA Technologies
3.1.5. Emergence of Molecular Residual Disease-Guided Cancer Management
3.1.6. Expansion of Companion Diagnostic Requirements
3.1.7. Digital Transformation of U.S. Pathology Workflows
3.1.8. Increasing Demand for Patient-Specific Treatment Planning
3.1.9. Growth of Value-Based Oncology Care Models
3.2. Restraints and Their Impact Analysis
3.2.1. High Cost of Advanced Molecular and Genomic Testing
3.2.2. Variable Reimbursement and Coverage for Emerging Biomarkers
3.2.3. Limited Clinical Utility Evidence for Selected Emerging Tests
3.2.4. Complexity of Genomic Data Interpretation
3.2.5. Tissue Availability and Pre-Analytical Sample Quality Constraints
3.2.6. Data Privacy, Cybersecurity and Genomic Information Risks
3.2.7. Oncology Workforce and Molecular Pathology Capacity Constraints
3.3. Opportunities and Their Impact Analysis
3.3.1. Tumor-Informed MRD Testing
3.3.2. Plasma-Based Comprehensive Genomic Profiling
3.3.3. Decentralized and Hospital-Based NGS Testing
3.3.4. AI-Assisted Digital Pathology
3.3.5. Multimodal Molecular and Clinical Decision Support
3.3.6. Personalized Radiation Oncology Planning
3.3.7. Community Oncology Precision Medicine Expansion
3.3.8. Companion Diagnostic Co-Development with Biopharma Companies
3.4. Challenges and Their Impact Analysis
3.4.1. Demonstrating Actionable Clinical Utility
3.4.2. Establishing Standardized Testing Pathways
3.4.3. Managing Rapid Biomarker and Therapy Evolution
3.4.4. Integration with Electronic Health Records and Oncology Information Systems
3.4.5. Expanding Precision Oncology Access Beyond Academic Centers
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Personalized Oncology Clinical Workflow Economics Analysis
3.7. Hospital and Laboratory Procurement Behavior Analysis
3.8. Diagnostic Turnaround Time and Clinical Decision Impact Analysis
3.9. Precision Oncology Reimbursement Sensitivity Analysis

What this section provides: This section explains the clinical, commercial, technological, reimbursement and operational forces shaping personalized oncology adoption and helps clients evaluate market upside, adoption barriers and execution risks.

4. U.S. Personalized Cancer Care Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Technology and Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Sample-to-Insight Personalized Oncology Workflow Analysis
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework for Oncology Devices and Companion Diagnostics
4.7.1. FDA In-Vitro Diagnostic Device Pathways
4.7.2. Companion Diagnostic Approval Framework
4.7.3. NGS-Based Oncology Device Regulation
4.7.4. Software as a Medical Device and AI Regulatory Considerations
4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Medicare Coverage for Molecular Diagnostic Testing
4.8.2. National and Local Coverage Determinations
4.8.3. Commercial Payer Coverage Dynamics
4.8.4. Molecular Diagnostic Coding and Payment Considerations
4.9. Laboratory Developed Test and Central Laboratory Competitive Impact
4.10. Import/Export Restrictions & Tariff Impact
4.11. Government Precision Medicine and Cancer Research Initiatives
4.12. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.13. Hospital, Cancer Center and Laboratory Value Analysis Decision Framework
4.14. Data Interoperability and Oncology Informatics Landscape

What this section provides: This section gives clients a complete view of the external personalized oncology environment, including FDA regulation, reimbursement, pricing, laboratory economics, technology integration, supply chains and institutional purchasing dynamics.

5. U.S. Personalized Cancer Care Devices Market – By Product & Device Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product & Device Type, 2025 & 2035 (%)
5.2. Molecular Profiling and NGS Systems
5.2.1. NGS Sequencing Instruments
5.2.2. Oncology Gene Panels and Assay Kits
5.2.3. Sample Preparation and Library Preparation Systems
5.2.4. Comprehensive Genomic Profiling Platforms
5.2.5. Genomic Interpretation and Reporting Systems
5.3. Companion Diagnostic and Biomarker Testing Devices
5.3.1. Immunohistochemistry-Based Companion Diagnostics
5.3.2. In-Situ Hybridization-Based Testing
5.3.3. PCR and Digital PCR-Based Companion Diagnostics
5.3.4. NGS-Based Companion Diagnostics
5.3.5. Protein and Immune Biomarker Testing Systems
5.4. Liquid Biopsy and ctDNA/MRD Systems
5.4.1. Plasma-Based Comprehensive Genomic Profiling
5.4.2. Tumor-Informed MRD Assays
5.4.3. Tumor-Naïve / Fixed-Panel MRD Assays
5.4.4. Resistance Mutation Monitoring Systems
5.4.5. Recurrence Surveillance Platforms
5.5. Digital Pathology and AI-Assisted Oncology Devices
5.5.1. Whole-Slide Imaging Systems
5.5.2. Digital Pathology Image Management Platforms
5.5.3. AI-Assisted Tumor Detection Systems
5.5.4. AI-Based Biomarker Quantification
5.5.5. Computational Pathology Decision-Support Platforms
5.6. Personalized Imaging, Navigation and Treatment-Planning Systems
5.6.1. Adaptive Radiation Therapy Planning Systems
5.6.2. AI-Assisted Radiation Contouring and Planning
5.6.3. Image-Guided Oncology Treatment Systems
5.6.4. Surgical Navigation and Intraoperative Guidance Systems
5.6.5. Patient-Specific Oncology Treatment Planning Software

What this section provides: This section identifies which personalized cancer care device categories generate the strongest revenue contribution and evaluates where molecular profiling, liquid biopsy, digital pathology and individualized treatment systems will create the highest growth through 2035.

6. U.S. Personalized Cancer Care Devices Market – By Cancer Type

6.1. Overview
6.1.1. Segment Share Analysis, By Cancer Type, 2025 & 2035 (%)
6.2. Lung Cancer
6.2.1. NSCLC Molecular Profiling
6.2.2. Companion Diagnostic Testing
6.2.3. Liquid Biopsy and Resistance Monitoring
6.2.4. MRD and Recurrence Surveillance
6.3. Breast Cancer
6.3.1. HER2 and Hormone Receptor Testing
6.3.2. Genomic Risk Assessment
6.3.3. BRCA and Other Molecular Biomarker Testing
6.3.4. ctDNA and Recurrence Monitoring
6.4. Colorectal Cancer
6.4.1. RAS/BRAF Molecular Testing
6.4.2. MSI/MMR Biomarker Testing
6.4.3. HER2 and Emerging Biomarker Testing
6.4.4. Post-Surgical MRD Monitoring
6.5. Prostate Cancer
6.5.1. Genomic Classifier Testing
6.5.2. HRR and BRCA Mutation Testing
6.5.3. Advanced Molecular Imaging and Treatment Planning
6.5.4. Treatment Response Monitoring
6.6. Hematologic Malignancies
6.6.1. Leukemia
6.6.2. Lymphoma
6.6.3. Multiple Myeloma
6.6.4. Molecular and Measurable Residual Disease Testing
6.7. Other Solid Tumors
6.7.1. Melanoma
6.7.2. Ovarian Cancer
6.7.3. Bladder Cancer
6.7.4. Pancreatic Cancer
6.7.5. Endometrial Cancer
6.7.6. Thyroid and Other Cancers

What this section provides: This section evaluates personalized device demand by cancer type and identifies where biomarker complexity, targeted therapy utilization, molecular monitoring and recurrence surveillance create the strongest commercial opportunities.

7. U.S. Personalized Cancer Care Devices Market – By Clinical Application

7.1. Overview
7.1.1. Segment Share Analysis, By Clinical Application, 2025 & 2035 (%)
7.2. Patient Stratification and Therapy Selection
7.2.1. Actionable Mutation Identification
7.2.2. Companion Diagnostic Eligibility Assessment
7.2.3. Immunotherapy Biomarker Assessment
7.2.4. Tumor-Agnostic Therapy Selection
7.3. Personalized Treatment Planning and Targeting
7.3.1. Radiation Treatment Planning
7.3.2. Image-Guided Treatment Delivery
7.3.3. Surgical Navigation
7.3.4. AI-Based Treatment Optimization
7.4. Molecular Residual Disease and Recurrence Monitoring
7.4.1. Post-Surgical MRD Assessment
7.4.2. Post-Adjuvant Treatment Monitoring
7.4.3. Molecular Recurrence Surveillance
7.4.4. Risk-Adaptive Treatment Escalation and De-Escalation Support
7.5. Treatment Response and Resistance Monitoring
7.5.1. Molecular Treatment Response Assessment
7.5.2. Acquired Resistance Mutation Detection
7.5.3. Therapy Switching Decision Support
7.6. Risk Assessment, Prognostic Profiling and Survivorship Management
7.6.1. Hereditary Cancer Risk Assessment
7.6.2. Genomic Prognostic Profiling
7.6.3. Recurrence Risk Stratification
7.6.4. Long-Term Survivorship Monitoring

What this section provides: This section helps clients determine where personalized cancer care devices are used across the patient journey, from therapy selection and treatment planning to response monitoring, MRD detection, recurrence surveillance and survivorship management.

8. U.S. Personalized Cancer Care Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.2. Hospitals and Integrated Health Systems
8.2.1. Large Integrated Delivery Networks
8.2.2. Regional Health Systems
8.2.3. Hospital-Based Oncology Programs
8.3. Academic Medical Centers and Comprehensive Cancer Centers
8.3.1. NCI-Designated Cancer Centers
8.3.2. Academic Oncology Hospitals
8.3.3. Clinical Trial and Translational Research Centers
8.4. Molecular Diagnostic and Reference Laboratories
8.4.1. National Reference Laboratories
8.4.2. Specialty Oncology Laboratories
8.4.3. Hospital-Owned Molecular Laboratories
8.5. Community Oncology Practices
8.5.1. Independent Oncology Practices
8.5.2. Multisite Community Oncology Networks
8.5.3. Physician-Owned Cancer Care Groups
8.6. Ambulatory Cancer Centers and Specialty Treatment Facilities
8.6.1. Radiation Oncology Centers
8.6.2. Ambulatory Cancer Treatment Centers
8.6.3. Specialty Diagnostic and Imaging Centers

What this section provides: This section explains which healthcare settings are expected to drive molecular testing, precision treatment planning, recurring surveillance and personalized oncology device purchasing across the United States.

9. U.S. Personalized Cancer Care Devices Market – By Technology Type

9.1. Overview
9.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
9.2. Next-Generation Sequencing Technologies
9.2.1. Targeted Gene Panels
9.2.2. Comprehensive Genomic Profiling
9.2.3. Whole-Exome and Expanded Sequencing Approaches
9.3. PCR and Digital PCR Technologies
9.3.1. Real-Time PCR
9.3.2. Multiplex PCR
9.3.3. Digital PCR
9.4. Immunohistochemistry, ISH and Protein Biomarker Technologies
9.4.1. Immunohistochemistry
9.4.2. Fluorescence In-Situ Hybridization
9.4.3. Other Protein and Tissue Biomarker Technologies
9.5. Liquid Biopsy and Circulating Biomarker Technologies
9.5.1. Circulating Tumor DNA
9.5.2. Circulating Tumor Cells
9.5.3. Cell-Free DNA and Other Circulating Biomarkers
9.5.4. Tumor-Informed Molecular Monitoring
9.6. Digital Pathology, AI and Computational Oncology Technologies
9.6.1. Whole-Slide Imaging
9.6.2. Machine Learning-Based Pathology
9.6.3. Multimodal Clinical Decision Support
9.6.4. AI-Assisted Imaging and Treatment Planning

What this section provides: This section evaluates the core technology platforms enabling personalized cancer care and identifies how sequencing, digital PCR, biomarker testing, liquid biopsy and AI-enabled oncology technologies are expected to evolve through 2035.

10. U.S. Personalized Cancer Care Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Cancer Incidence and Patient Pool Analysis
10.1.4. Regional Cancer Center and Molecular Laboratory Infrastructure Analysis
10.1.5. Regional Precision Oncology Adoption Analysis
10.1.6. Regional Reimbursement and Coverage Dynamics
10.1.7. Regional Hospital, Laboratory and Oncology Practice Procurement Dynamics
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region Personalized Cancer Care Device Key Companies and Precision Oncology Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Personalized Cancer Care Device Key Companies and Precision Oncology Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region Personalized Cancer Care Device Key Companies and Precision Oncology Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Personalized Cancer Care Device Key Companies and Precision Oncology Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product & Device Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed four-region and all-50-state analysis, helping clients identify precision-oncology adoption hotspots, high-value cancer markets, molecular-testing infrastructure, leading cancer-center clusters and state-level commercial opportunities.

11. U.S. Personalized Cancer Care Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Competitive Benchmarking by Personalized Oncology Capability
11.3.1. Comprehensive Genomic Profiling
11.3.2. Companion Diagnostics
11.3.3. Liquid Biopsy
11.3.4. Molecular Residual Disease
11.3.5. Digital Pathology and AI
11.3.6. Personalized Imaging and Treatment Planning
11.4. Company Profiles
11.4.1. Roche Diagnostics
11.4.2. Foundation Medicine
11.4.3. Guardant Health
11.4.4. Natera
11.4.5. Illumina
11.4.6. Thermo Fisher Scientific
11.4.7. QIAGEN
11.4.8. Agilent Technologies
11.4.9. Abbott Laboratories
11.4.10. Myriad Genetics
11.4.11. Exact Sciences
11.4.12. Caris Life Sciences
11.4.13. Tempus AI
11.4.14. NeoGenomics Laboratories
11.4.15. Personalis
11.4.16. Adaptive Biotechnologies
11.4.17. Danaher / Leica Biosystems
11.4.18. Bio-Rad Laboratories
11.4.19. Hologic
11.4.20. Siemens Healthineers / Varian
11.4.21. GE HealthCare
11.4.22. Philips
11.4.23. Elekta
11.4.24. Paige
11.4.25. PathAI

Note: Each company profile will include company overview, personalized cancer care device and diagnostic portfolio, U.S. market strategy, financial and commercial positioning, FDA/regulatory status, clinical evidence pipeline, biomarker and pharmaceutical partnerships, technology differentiation, acquisitions and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, technology positioning, clinical and regulatory differentiation, partnership intelligence and strategic insights on major personalized cancer care device companies.

12. U.S. Personalized Cancer Care Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Tumor-Informed Molecular Residual Disease Testing
12.2.2. Ultra-Sensitive ctDNA and Liquid Biopsy
12.2.3. Decentralized and Rapid NGS Platforms
12.2.4. AI-Assisted Digital Pathology
12.2.5. Multimodal Molecular and Clinical Decision Support
12.2.6. Adaptive Radiation Oncology and AI Treatment Planning
12.2.7. Spatial Biology and Next-Generation Tumor Profiling
12.2.8. Longitudinal Molecular Cancer Monitoring
12.3. Emerging Business Trends
12.3.1. Shift from One-Time Testing to Longitudinal Testing
12.3.2. Diagnostic-Biopharma Co-Development Models
12.3.3. Expansion of Community Precision Oncology
12.3.4. Enterprise Molecular Testing Standardization
12.3.5. Real-World Data and Outcomes-Linked Diagnostics
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Technology Adoption Curve, 2026–2035
12.7. Potential Market Disruption and Consolidation Outlook

What this section provides: This section prepares clients for future technology shifts, reimbursement developments, new testing models, market consolidation, investment opportunities and potential personalized oncology adoption scenarios through 2035.

13. U.S. Personalized Cancer Care Devices Market: Strategic Recommendations

13.1. Recommendations for Molecular Diagnostic and Device Manufacturers
13.2. Recommendations for Hospitals and Integrated Health Systems
13.3. Recommendations for Academic and Comprehensive Cancer Centers
13.4. Recommendations for Molecular and Reference Laboratories
13.5. Recommendations for Community Oncology Networks
13.6. Recommendations for Pharmaceutical and Biopharmaceutical Partners
13.7. Recommendations for Investors and Private Equity Firms
13.8. Recommendations for Distributors and Technology Channel Partners
13.9. Recommendations for New Entrants and Startups
13.10. U.S. Go-to-Market Strategy Considerations
13.10.1. Clinical Evidence Strategy
13.10.2. FDA and Regulatory Strategy
13.10.3. Reimbursement and Market Access Strategy
13.10.4. Cancer Center and KOL Adoption Strategy
13.10.5. Community Oncology Expansion Strategy
13.11. Product Positioning and Portfolio Expansion Guidance
13.12. Companion Diagnostic Partnership Strategy
13.13. State and Regional Expansion Prioritization

What this section provides: This section converts market intelligence into actionable strategy for product development, regulatory planning, reimbursement, clinical evidence generation, market entry, partnerships, geographic expansion and competitive differentiation.

14. U.S. Personalized Cancer Care Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer
14.6. Personalized Oncology Device Classification Limitation
14.7. Regulatory and Reimbursement Change Limitation

What this section provides: This section clarifies the report’s market-definition boundaries, data-use terms, forecasting assumptions, regulatory considerations, legal limitations and interpretation of personalized cancer care device categories.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Personalized Cancer Care Devices Market: Market Definition and Scope
TABLE 3: U.S. Personalized Cancer Care Devices Market: Research Methodology Framework
TABLE 4: U.S. Personalized Cancer Care Devices Market: Key Assumptions
TABLE 5: U.S. Personalized Cancer Care Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Personalized Cancer Care Devices Market: Stakeholder Analysis
TABLE 7: U.S. Personalized Cancer Care Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Personalized Cancer Care Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Personalized Cancer Care Devices Market: Market Attractiveness Index
TABLE 10: U.S. Personalized Cancer Care Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Personalized Cancer Care Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Personalized Cancer Care Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Personalized Cancer Care Devices Market: High-Growth Opportunity Areas
TABLE 14: U.S. Personalized Cancer Care Devices Market: Drivers; Impact Analysis
TABLE 15: U.S. Personalized Cancer Care Devices Market: Restraints; Impact Analysis
TABLE 16: U.S. Personalized Cancer Care Devices Market: Opportunities; Impact Analysis
TABLE 17: U.S. Personalized Cancer Care Devices Market: Challenges; Impact Analysis
TABLE 18: U.S. Personalized Cancer Care Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. Personalized Cancer Care Devices Market: Personalized Oncology Clinical Workflow Economics Matrix
TABLE 20: U.S. Personalized Cancer Care Devices Market: Hospital and Laboratory Procurement Behavior Matrix
TABLE 21: U.S. Personalized Cancer Care Devices Market: Diagnostic Turnaround Time and Clinical Decision Impact
TABLE 22: U.S. Personalized Cancer Care Devices Market: Precision Oncology Reimbursement Sensitivity Analysis
TABLE 23: U.S. Personalized Cancer Care Devices Market: PESTEL Analysis
TABLE 24: U.S. Personalized Cancer Care Devices Market: Porter’s Five Forces Analysis
TABLE 25: U.S. Personalized Cancer Care Devices Market: Pricing Trend Analysis by Technology and Region, 2025–2035
TABLE 26: U.S. Personalized Cancer Care Devices Market: Value Chain Analysis
TABLE 27: U.S. Personalized Cancer Care Devices Market: Supply Chain Analysis
TABLE 28: U.S. Personalized Cancer Care Devices Market: Sample-to-Insight Workflow Analysis
TABLE 29: U.S. Personalized Cancer Care Devices Market: Application & Innovation Landscape
TABLE 30: U.S. Personalized Cancer Care Devices Market: FDA Regulatory Framework Analysis
TABLE 31: U.S. Personalized Cancer Care Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 32: U.S. Personalized Cancer Care Devices Market: Laboratory Developed Test Competitive Impact
TABLE 33: U.S. Personalized Cancer Care Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 34: U.S. Personalized Cancer Care Devices Market: Government Precision Medicine and Cancer Initiatives
TABLE 35: U.S. Personalized Cancer Care Devices Market: Geopolitical and Supply-Chain Risk Matrix
TABLE 36: U.S. Personalized Cancer Care Devices Market: Hospital, Cancer Center and Laboratory Value Analysis Framework
TABLE 37: U.S. Personalized Cancer Care Devices Market: Data Interoperability and Oncology Informatics Landscape
TABLE 38: U.S. Personalized Cancer Care Devices Market: Product & Device Type Snapshot, 2025
TABLE 39: Segment Dashboard; Definition and Scope, by Product & Device Type
TABLE 40: U.S. Personalized Cancer Care Devices Market, by Product & Device Type, 2021–2035 (US$ Billion)
TABLE 41: U.S. Personalized Cancer Care Devices Market: Segment Share Analysis, by Product & Device Type, 2025 & 2035 (%)
TABLE 42: U.S. Personalized Cancer Care Devices Market: Molecular Profiling and NGS Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: U.S. Personalized Cancer Care Devices Market: Companion Diagnostic and Biomarker Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. Personalized Cancer Care Devices Market: Liquid Biopsy and ctDNA/MRD Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Personalized Cancer Care Devices Market: Digital Pathology and AI-Assisted Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Personalized Cancer Care Devices Market: Personalized Imaging, Navigation and Treatment-Planning Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Personalized Cancer Care Devices Market: Cancer Type Snapshot, 2025
TABLE 48: Segment Dashboard; Definition and Scope, by Cancer Type
TABLE 49: U.S. Personalized Cancer Care Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 50: U.S. Personalized Cancer Care Devices Market: Segment Share Analysis, by Cancer Type, 2025 & 2035 (%)
TABLE 51: U.S. Personalized Cancer Care Devices Market: Lung Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Personalized Cancer Care Devices Market: Breast Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. Personalized Cancer Care Devices Market: Colorectal Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Personalized Cancer Care Devices Market: Prostate Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Personalized Cancer Care Devices Market: Hematologic Malignancies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Personalized Cancer Care Devices Market: Other Solid Tumors Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Personalized Cancer Care Devices Market: Clinical Application Snapshot, 2025
TABLE 58: Segment Dashboard; Definition and Scope, by Clinical Application
TABLE 59: U.S. Personalized Cancer Care Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 60: U.S. Personalized Cancer Care Devices Market: Segment Share Analysis, by Clinical Application, 2025 & 2035 (%)
TABLE 61: U.S. Personalized Cancer Care Devices Market: Patient Stratification and Therapy Selection Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. Personalized Cancer Care Devices Market: Personalized Treatment Planning and Targeting Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Personalized Cancer Care Devices Market: Molecular Residual Disease and Recurrence Monitoring Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Personalized Cancer Care Devices Market: Treatment Response and Resistance Monitoring Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Personalized Cancer Care Devices Market: Risk Assessment, Prognostic Profiling and Survivorship Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Personalized Cancer Care Devices Market: End User Snapshot, 2025
TABLE 67: Segment Dashboard; Definition and Scope, by End User
TABLE 68: U.S. Personalized Cancer Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 69: U.S. Personalized Cancer Care Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 70: U.S. Personalized Cancer Care Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. Personalized Cancer Care Devices Market: Academic Medical Centers and Comprehensive Cancer Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Personalized Cancer Care Devices Market: Molecular Diagnostic and Reference Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Personalized Cancer Care Devices Market: Community Oncology Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Personalized Cancer Care Devices Market: Ambulatory Cancer Centers and Specialty Treatment Facilities Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Personalized Cancer Care Devices Market: Technology Type Snapshot, 2025
TABLE 76: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 77: U.S. Personalized Cancer Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 78: U.S. Personalized Cancer Care Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 79: U.S. Personalized Cancer Care Devices Market: Next-Generation Sequencing Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: U.S. Personalized Cancer Care Devices Market: PCR and Digital PCR Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. Personalized Cancer Care Devices Market: IHC, ISH and Protein Biomarker Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. Personalized Cancer Care Devices Market: Liquid Biopsy and Circulating Biomarker Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. Personalized Cancer Care Devices Market: Digital Pathology, AI and Computational Oncology Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. Personalized Cancer Care Devices Market: Regional Snapshot, 2025
TABLE 85: Segment Dashboard; Definition and Scope, by Region
TABLE 86: U.S. Personalized Cancer Care Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 87: U.S. Personalized Cancer Care Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 88: West Region U.S. Personalized Cancer Care Devices Market: Regional Overview and Trends
TABLE 89: West Region U.S. Personalized Cancer Care Devices Market: Key Companies and Precision Oncology Ecosystem
TABLE 90: West Region U.S. Personalized Cancer Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 91: West Region U.S. Personalized Cancer Care Devices Market, by Product & Device Type, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. Personalized Cancer Care Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Personalized Cancer Care Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Personalized Cancer Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. Personalized Cancer Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 96: California Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Washington Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Arizona Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Colorado Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Oregon Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Utah Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Nevada Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: New Mexico Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Idaho Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Montana Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Wyoming Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Alaska Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Hawaii Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Northeast Region U.S. Personalized Cancer Care Devices Market: Regional Overview and Trends
TABLE 110: Northeast Region U.S. Personalized Cancer Care Devices Market: Key Companies and Precision Oncology Ecosystem
TABLE 111: Northeast Region U.S. Personalized Cancer Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. Personalized Cancer Care Devices Market, by Product & Device Type, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. Personalized Cancer Care Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 114: Northeast Region U.S. Personalized Cancer Care Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. Personalized Cancer Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 116: Northeast Region U.S. Personalized Cancer Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 117: New York Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Massachusetts Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: New Jersey Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Pennsylvania Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Connecticut Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Maine Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Vermont Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: New Hampshire Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Rhode Island Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: Delaware Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: South Region U.S. Personalized Cancer Care Devices Market: Regional Overview and Trends
TABLE 128: South Region U.S. Personalized Cancer Care Devices Market: Key Companies and Precision Oncology Ecosystem
TABLE 129: South Region U.S. Personalized Cancer Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 130: South Region U.S. Personalized Cancer Care Devices Market, by Product & Device Type, 2021–2035 (US$ Billion)
TABLE 131: South Region U.S. Personalized Cancer Care Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 132: South Region U.S. Personalized Cancer Care Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 133: South Region U.S. Personalized Cancer Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 134: South Region U.S. Personalized Cancer Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 135: Texas Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Florida Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Georgia Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: North Carolina Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Tennessee Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: South Carolina Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Alabama Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Mississippi Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Louisiana Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Arkansas Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Kentucky Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Oklahoma Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Virginia Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Maryland Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: West Virginia Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Midwest Region U.S. Personalized Cancer Care Devices Market: Regional Overview and Trends
TABLE 151: Midwest Region U.S. Personalized Cancer Care Devices Market: Key Companies and Precision Oncology Ecosystem
TABLE 152: Midwest Region U.S. Personalized Cancer Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 153: Midwest Region U.S. Personalized Cancer Care Devices Market, by Product & Device Type, 2021–2035 (US$ Billion)
TABLE 154: Midwest Region U.S. Personalized Cancer Care Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 155: Midwest Region U.S. Personalized Cancer Care Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 156: Midwest Region U.S. Personalized Cancer Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 157: Midwest Region U.S. Personalized Cancer Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 158: Illinois Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Ohio Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Michigan Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: Minnesota Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: Indiana Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: Wisconsin Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Missouri Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: Iowa Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: Kansas Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: Nebraska Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 168: North Dakota Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 169: South Dakota Personalized Cancer Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 170: U.S. Personalized Cancer Care Devices Market: Competitive Landscape Snapshot, 2025
TABLE 171: U.S. Personalized Cancer Care Devices Market: Key Company Market Share Analysis, 2025
TABLE 172: U.S. Personalized Cancer Care Devices Market: Company Positioning Matrix
TABLE 173: U.S. Personalized Cancer Care Devices Market: Personalized Oncology Capability Benchmarking
TABLE 174: U.S. Personalized Cancer Care Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 175: Roche Diagnostics: Company Profile
TABLE 176: Foundation Medicine: Company Profile
TABLE 177: Guardant Health: Company Profile
TABLE 178: Natera: Company Profile
TABLE 179: Illumina: Company Profile
TABLE 180: Thermo Fisher Scientific: Company Profile
TABLE 181: QIAGEN: Company Profile
TABLE 182: Agilent Technologies: Company Profile
TABLE 183: Abbott Laboratories: Company Profile
TABLE 184: Myriad Genetics: Company Profile
TABLE 185: Exact Sciences: Company Profile
TABLE 186: Caris Life Sciences: Company Profile
TABLE 187: Tempus AI: Company Profile
TABLE 188: NeoGenomics Laboratories: Company Profile
TABLE 189: Personalis: Company Profile
TABLE 190: Adaptive Biotechnologies: Company Profile
TABLE 191: Danaher / Leica Biosystems: Company Profile
TABLE 192: Bio-Rad Laboratories: Company Profile
TABLE 193: Hologic: Company Profile
TABLE 194: Siemens Healthineers / Varian: Company Profile
TABLE 195: GE HealthCare: Company Profile
TABLE 196: Philips: Company Profile
TABLE 197: Elekta: Company Profile
TABLE 198: Paige: Company Profile
TABLE 199: PathAI: Company Profile
TABLE 200: U.S. Personalized Cancer Care Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 201: U.S. Personalized Cancer Care Devices Market: Disruptive Technologies Impact Matrix
TABLE 202: U.S. Personalized Cancer Care Devices Market: Emerging Business Trends
TABLE 203: U.S. Personalized Cancer Care Devices Market: Business Opportunities for Startups and Existing Players
TABLE 204: U.S. Personalized Cancer Care Devices Market: Investment Prioritization Matrix
TABLE 205: U.S. Personalized Cancer Care Devices Market: Technology Adoption Curve, 2026–2035
TABLE 206: U.S. Personalized Cancer Care Devices Market: Potential Market Disruption and Consolidation Outlook
TABLE 207: U.S. Personalized Cancer Care Devices Market: Strategic Recommendations for Molecular Diagnostic and Device Manufacturers
TABLE 208: U.S. Personalized Cancer Care Devices Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 209: U.S. Personalized Cancer Care Devices Market: Strategic Recommendations for Academic and Comprehensive Cancer Centers
TABLE 210: U.S. Personalized Cancer Care Devices Market: Strategic Recommendations for Molecular and Reference Laboratories
TABLE 211: U.S. Personalized Cancer Care Devices Market: Strategic Recommendations for Community Oncology Networks
TABLE 212: U.S. Personalized Cancer Care Devices Market: Strategic Recommendations for Pharmaceutical and Biopharmaceutical Partners
TABLE 213: U.S. Personalized Cancer Care Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 214: U.S. Personalized Cancer Care Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 215: U.S. Personalized Cancer Care Devices Market: U.S. Go-to-Market Strategy Considerations
TABLE 216: U.S. Personalized Cancer Care Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 217: U.S. Personalized Cancer Care Devices Market: Companion Diagnostic Partnership Strategy
TABLE 218: U.S. Personalized Cancer Care Devices Market: State and Regional Expansion Prioritization
TABLE 219: U.S. Personalized Cancer Care Devices Market: Scope Limitation
TABLE 220: U.S. Personalized Cancer Care Devices Market: Data Use Limitation
TABLE 221: U.S. Personalized Cancer Care Devices Market: Forecasting Limitation
TABLE 222: U.S. Personalized Cancer Care Devices Market: Legal Disclaimer
TABLE 223: U.S. Personalized Cancer Care Devices Market: Third-Party Data Disclaimer
TABLE 224: U.S. Personalized Cancer Care Devices Market: Personalized Oncology Device Classification Limitation
TABLE 225: U.S. Personalized Cancer Care Devices Market: Regulatory and Reimbursement Change Limitation

List of Figures

FIGURE 1: U.S. Personalized Cancer Care Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem and Stakeholder Map
FIGURE 4: U.S. Personalized Cancer Care Devices Market Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 5: U.S. Personalized Cancer Care Devices Market Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 6: U.S. Personalized Cancer Care Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Personalized Oncology Clinical Workflow Economics Framework
FIGURE 11: Hospital and Laboratory Procurement Decision Framework
FIGURE 12: Diagnostic Turnaround Time and Clinical Decision Impact Framework
FIGURE 13: PESTEL Analysis
FIGURE 14: Porter’s Five Forces Analysis
FIGURE 15: Value Chain Analysis
FIGURE 16: Supply Chain Analysis
FIGURE 17: Sample-to-Insight Personalized Oncology Workflow
FIGURE 18: FDA Regulatory and Companion Diagnostic Framework
FIGURE 19: CMS Reimbursement and Coverage Landscape
FIGURE 20: Product & Device Type Segment Market Share Analysis, 2025 & 2035
FIGURE 21: Product & Device Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Molecular Profiling and NGS Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Companion Diagnostic and Biomarker Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Liquid Biopsy and ctDNA/MRD Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Digital Pathology and AI-Assisted Oncology Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Personalized Imaging, Navigation and Treatment-Planning Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Cancer Type Segment Market Share Analysis, 2025 & 2035
FIGURE 28: Cancer Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Lung Cancer Personalized Cancer Care Devices Market Forecast and Trend Analysis, 2021–2035
FIGURE 30: Breast Cancer Personalized Cancer Care Devices Market Forecast and Trend Analysis, 2021–2035
FIGURE 31: Colorectal Cancer Personalized Cancer Care Devices Market Forecast and Trend Analysis, 2021–2035
FIGURE 32: Prostate Cancer Personalized Cancer Care Devices Market Forecast and Trend Analysis, 2021–2035
FIGURE 33: Hematologic Malignancies Personalized Cancer Care Devices Market Forecast and Trend Analysis, 2021–2035
FIGURE 34: Other Solid Tumors Personalized Cancer Care Devices Market Forecast and Trend Analysis, 2021–2035
FIGURE 35: Clinical Application Segment Market Share Analysis, 2025 & 2035
FIGURE 36: Clinical Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Patient Stratification and Therapy Selection Market Forecast and Trend Analysis, 2021–2035
FIGURE 38: Personalized Treatment Planning and Targeting Market Forecast and Trend Analysis, 2021–2035
FIGURE 39: MRD and Recurrence Monitoring Market Forecast and Trend Analysis, 2021–2035
FIGURE 40: Treatment Response and Resistance Monitoring Market Forecast and Trend Analysis, 2021–2035
FIGURE 41: Risk Assessment, Prognostic Profiling and Survivorship Management Market Forecast and Trend Analysis, 2021–2035
FIGURE 42: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 43: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Hospitals and Integrated Health Systems Market Forecast and Trend Analysis, 2021–2035
FIGURE 45: Academic Medical Centers and Comprehensive Cancer Centers Market Forecast and Trend Analysis, 2021–2035
FIGURE 46: Molecular Diagnostic and Reference Laboratories Market Forecast and Trend Analysis, 2021–2035
FIGURE 47: Community Oncology Practices Market Forecast and Trend Analysis, 2021–2035
FIGURE 48: Ambulatory Cancer Centers and Specialty Treatment Facilities Market Forecast and Trend Analysis, 2021–2035
FIGURE 49: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 50: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Next-Generation Sequencing Technologies Market Forecast and Trend Analysis, 2021–2035
FIGURE 52: PCR and Digital PCR Technologies Market Forecast and Trend Analysis, 2021–2035
FIGURE 53: IHC, ISH and Protein Biomarker Technologies Market Forecast and Trend Analysis, 2021–2035
FIGURE 54: Liquid Biopsy and Circulating Biomarker Technologies Market Forecast and Trend Analysis, 2021–2035
FIGURE 55: Digital Pathology, AI and Computational Oncology Technologies Market Forecast and Trend Analysis, 2021–2035
FIGURE 56: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 57: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: West Region U.S. Personalized Cancer Care Devices Market Share and Leading Players, 2025
FIGURE 59: West Region Market Share Analysis by State, 2025
FIGURE 60: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: California Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Washington Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Arizona Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Colorado Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Oregon Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Utah Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Nevada Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: New Mexico Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Idaho Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Montana Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Wyoming Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Alaska Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Hawaii Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Northeast Region U.S. Personalized Cancer Care Devices Market Share and Leading Players, 2025
FIGURE 75: Northeast Region Market Share Analysis by State, 2025
FIGURE 76: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: New York Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Massachusetts Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: New Jersey Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Pennsylvania Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Connecticut Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Maine Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Vermont Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: New Hampshire Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Rhode Island Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Delaware Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: South Region U.S. Personalized Cancer Care Devices Market Share and Leading Players, 2025
FIGURE 88: South Region Market Share Analysis by State, 2025
FIGURE 89: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Texas Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Florida Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Georgia Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: North Carolina Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Tennessee Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: South Carolina Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Alabama Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Mississippi Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Louisiana Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Arkansas Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Kentucky Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Oklahoma Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Virginia Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Maryland Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: West Virginia Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Midwest Region U.S. Personalized Cancer Care Devices Market Share and Leading Players, 2025
FIGURE 106: Midwest Region Market Share Analysis by State, 2025
FIGURE 107: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Illinois Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Ohio Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Michigan Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Minnesota Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Indiana Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Wisconsin Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Missouri Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Iowa Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Kansas Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Nebraska Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: North Dakota Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: South Dakota Personalized Cancer Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 121: Company Positioning Matrix
FIGURE 122: Personalized Oncology Capability Benchmarking
FIGURE 123: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 124: Personalized Cancer Care Device Innovation Roadmap
FIGURE 125: Liquid Biopsy and ctDNA Adoption Roadmap
FIGURE 126: Molecular Residual Disease Opportunity Map
FIGURE 127: AI-Assisted Digital Pathology Adoption Roadmap
FIGURE 128: Comprehensive Genomic Profiling Expansion Roadmap
FIGURE 129: Future Market Scenario Analysis, 2026–2035
FIGURE 130: Disruptive Technologies Impact Matrix
FIGURE 131: Emerging Business Trends Matrix
FIGURE 132: Technology Adoption Curve, 2026–2035
FIGURE 133: Investment Prioritization Matrix
FIGURE 134: Strategic Growth Roadmap for U.S. Personalized Cancer Care Device Companies
FIGURE 135: U.S. Go-to-Market Strategy Framework
FIGURE 136: Companion Diagnostic Partnership Strategy Framework
FIGURE 137: State and Regional Expansion Prioritization Framework
FIGURE 138: Product Positioning and Portfolio Expansion Framework
FIGURE 139: Report Scope and Disclaimer Framework